Live Breaking News & Updates on Enliven therapeutics inc

Stay informed with the latest breaking news from Enliven therapeutics inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Enliven therapeutics inc and stay connected to the pulse of your community

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.5%

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) shares were up 7.5% on Monday . The stock traded as high as $18.63 and last traded at $18.47. Approximately 88,659 shares changed hands during trading, a decline of 61% from the average daily volume of 228,233 shares. The stock had previously closed at $17.18. Analyst Ratings […]

China , Samuel-kintz , Nasdaq , Securities-exchange-commission , Enliven-therapeutics-inc , Exchange-traded-concepts , Mirae-asset-global-investments-co , China-universal-asset-management-co , Partners-vi-llc , Sg-americas-securities , Enliven-therapeutics , Get-free-report

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $438,025.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 17,500 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $25.03, for a total value of $438,025.00. The sale was disclosed in a document filed with the Securities & […]

Anish-patel , Nasdaq , Vanguard-group-inc , Enliven-therapeutics-company-profile , Geode-capital-management , Blackrock-inc , Enliven-therapeutics-inc , Citadel-advisors , Securities-exchange-commission , Enliven-therapeutics , Get-free-report , Exchange-commission

Anish Patel Sells 17,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 17,500 shares of the stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.03, for a total value of $438,025.00. The sale was disclosed in a legal filing with the SEC, which is accessible through […]

Canada , Anish-patel , Barclays-plc , Citadel-advisors , Royal-bank , Nasdaq , Vanguard-group-inc , Goldman-sachs-group-inc , Enliven-therapeutics-inc , Enliven-therapeutics , Get-free-report , Sachs-group

Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was up 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30. Analyst Ratings […]

China , Canada , Richarda-heyman , Nasdaq , Ameritas-investment-partners-inc , Enliven-therapeutics-inc , Partners-vi-llc , Royal-bank , Tower-research-capital , Securities-exchange-commission , China-universal-asset-management-co

Enliven Therapeutics, Inc (ELVN) Files for 6.43M Share Offering by Selling Stockholders

Enliven Therapeutics, Inc (ELVN) Files for 6.43M Share Offering by Selling Stockholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Enliven-therapeutics-inc , Enliven-therapeutics ,

Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was up 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30. Analyst Ratings […]

China , Canada , Richarda-heyman , Royal-bank , Enliven-therapeutics-inc , Partners-vi-llc , Nasdaq , Ameritas-investment-partners-inc , China-universal-asset-management-co , Securities-exchange-commission , Tower-research-capital

Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) rose 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30. Wall Street Analyst […]

Anish-patel , Blackrock-inc , Securities-exchange-commission , Geode-capital-management , Citadel-advisors , Partners-vi-llc , Enliven-therapeutics-inc , Vanguard-group-inc , Nasdaq , Enliven-therapeutics , Get-free-report , Exchange-commission

Enliven Therapeutics, Inc (ELVN) Reports Positive Proof of Concept Data from Phase 1 Trial of ELVN-001

Enliven Therapeutics, Inc (ELVN) Reports Positive Proof of Concept Data from Phase 1 Trial of ELVN-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sam-kintz , Helen-collins , Fabian-lang , Enliven-therapeutics-inc , Company-nasdaq , Goethe-university-hospital , Enliven-therapeutics , Goethe-university , Chief-medical-officer , Chief-executive-officer ,

Enliven Therapeutics Announces Positive Proof of Concept

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of...

Boulder , Colorado , United-states , Helen-collins , Sam-kintz , Fabian-lang , Michael-mauro , Company-event , Securities-exchange , Goethe-university-hospital , Memorial-sloan-kettering-cancer-center , Exchange-commission

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Achieved initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative...

Boulder , Colorado , United-states , Michael-mauro , Fabian-lang , Sam-kintz , Helen-collins , Company-nasdaq , Exchange-commission , Enliven-therapeutics-inc , Globenewswire-inc , Goethe-university-hospital